A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 100
Summary
- Conditions
- Colorectal Cancer
- Hormone Receptor Positive Breast Carcinoma
- Metastatic Castration Resistant Prostate Cancer
- Neoplasm Malignant
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: single-agent and combination therapy dose-escalation followed by cohort-expansionMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03845166
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon